KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

James F Howard, Francesco Saccà, Sarah Hoffmann, Shahram Attarian, Jan L De Bleecker, Jon Beauchamp, Edward Brauer, René Kerstens, John Vissing, Andreas Meisel, ADAPT Study Group

J Neurol 273(6) 363

PMID42234197
PMCIDPMC13233976
DOI10.1007/s00415-026-13877-z
发表日期2026-06-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图。
摘要

摘要

BACKGROUND: The ADAPT phase 3 trial (NCT03669588) showed efgartigimod was well tolerated and efficacious in acetylcholine receptor antibody-positive (AChR-Ab +) patients with generalized myasthenia gravis (gMG). This analysis utilized data from the ADAPT trial to investigate the efficacy and safety of efgartigimod in different patient subgroups. METHODS: ADAPT included a broad population of AChR-Ab + participants who received a stable dose of ≥ 1 (any) treatment for gMG and were randomized 1:1 to efgartigimod (10 mg/kg) or placebo (administered as four once-weekly infusions per cycle) for 26 weeks. Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) responder rates in cycles 1 and 2, and rates of treatment-emergent adverse events (TEAEs) were analyzed in the following patient subgroups: history of nonsteroidal immunosuppressive treatment (NSIST), concomitant use of gMG treatments throughout the study, and baseline patient and disease characteristics, including time since diagnosis, age, baseline MG-ADL score, body mass index (BMI), sex, and prior thymectomy. RESULTS: In total, 129 AChR-Ab + participants were included (efgartigimod, n = 65; placebo, n = 64). Across all subgroups, higher MG-ADL and QMG responder rates were observed in participants treated with efgartigimod versus placebo during cycles 1 and 2. Rates of TEAEs were similar between participants treated with efgartigimod and placebo, regardless of concomitant gMG treatment type. CONCLUSION: Similar to outcomes observed in the ADAPT overall population, efgartigimod was well tolerated and efficacious across a broad range of patients, regardless of NSIST treatment history, concomitant use of gMG treatments, or baseline patient and disease characteristics. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03669588 (registered September 13, 2018).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Proportion of a MG-ADL and b QMG responders in cycle 1 by use of gMG treatments during the original study or NSISTs prior to study initiation. One patient in the placebo group was not receiving any concomitant gMG treatment during the original study and was excluded from respective analyses. AChE acetylcholinesterase, CI confidence interval, EFG efgartigimod, g MG generalized myasthenia gravis, MG-ADL myasthenia gravis activities of daily living, NSIST nonsteroidal immunosuppressive treatment, PLA placebo, QMG quantitative myasthenia gravis
非 KM Figure
Fig. 2Proportion of a MG-ADL and b QMG responders in cycle 1 by baseline patient and disease characteristics. BMI body mass index, CI confidence interval, EFG efgartigimod, MG-ADL myasthenia gravis activities of daily living, PLA placebo, QMG quantitative myasthenia gravis
非 KM Figure